Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

If you’re prescribed Zepbound, your doctor or another healthcare professional will likely give you the first dose in their office. Then they’ll show you or someone else how to inject your ...

Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

TOKYO -- U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat.

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...